IKT-001 for pulmonary arterial hypertension
Part of Lungs & breathing clinical trials.
This study tests a new medicine called IKT-001 for people with pulmonary arterial hypertension (PAH). It aims to see if IKT-001 helps improve exercise ability and other symptoms when added to current PAH therapies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a specific type of PAH (idiopathic, heritable, drug/toxin-induced, with connective tissue disease, or after congenital heart repair).
- Your body mass index (BMI) is between 18.5 and 35.
- You can walk between 100 and 475 meters in six minutes.
- You have been on stable PAH medications for at least 90 days (but not sotatercept).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a new form of tacrolimus (a medication that helps calm the immune system) can improve breathing and exercise ability in people with pulmonary arterial hypertension (high blood pressure in the lungs) who are still limited despite current treatments. The study aims to see if this drug can help patients walk farther and feel less short of breath.
This trial tests an investigational drug called NS-863 for people with pulmonary arterial hypertension (PAH). It aims to see if it can improve exercise ability and symptoms when added to your current PAH therapy.
This study tests a new drug called sotatercept to help people with pulmonary arterial hypertension (PAH)—a condition where blood vessels in the lungs become too narrow, making the heart work harder. The drug may help improve how well your lungs and heart work together.
This trial tests an inhaled medication (TPIP) that opens blood vessels in the lungs to help you breathe easier and be more active. It is for people with PAH who are already on stable treatment and have moderate symptoms.
This trial tests an experimental drug called HS235 for people with pulmonary arterial hypertension (PAH), a condition of high blood pressure in the lungs. It aims to see if the drug can help improve symptoms and exercise ability.
This Phase 2 trial tests sotatercept, a medicine that targets the blood-vessel changes in pulmonary arterial hypertension (PAH), in children. It may help improve how well the heart and lungs work by changing the underlying disease process.
Hear when a new Pulmonary Arterial Hypertension trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.